INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,456,333 | +0.5% | 822,823 | +33.3% | 0.00% | – |
| Q2 2023 | $3,439,246 | +148.8% | 617,459 | +156.0% | 0.00% | – |
| Q1 2023 | $1,382,121 | +566343.0% | 241,208 | +3.5% | 0.00% | – |
| Q4 2022 | $244 | -100.0% | 233,126 | -0.2% | 0.00% | – |
| Q3 2022 | $626,000 | -39.5% | 233,685 | +7.7% | 0.00% | – |
| Q2 2022 | $1,034,000 | +36.1% | 216,925 | +16.6% | 0.00% | – |
| Q1 2022 | $760,000 | -39.4% | 186,007 | +1.1% | 0.00% | – |
| Q4 2021 | $1,255,000 | -45.5% | 184,019 | -7.4% | 0.00% | – |
| Q3 2021 | $2,302,000 | -24.8% | 198,624 | +10.5% | 0.00% | – |
| Q2 2021 | $3,061,000 | +2.8% | 179,672 | +19.5% | 0.00% | – |
| Q1 2021 | $2,977,000 | +35.5% | 150,361 | +41.3% | 0.00% | – |
| Q4 2020 | $2,197,000 | -14.9% | 106,446 | +8.3% | 0.00% | -100.0% |
| Q3 2020 | $2,583,000 | – | 98,284 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 1,009,117 | $26,529,000 | 9.44% |
| YALE UNIVERSITY | 113,502 | $2,984,000 | 9.13% |
| Sofinnova Investments, Inc. | 2,028,308 | $53,324,000 | 3.95% |
| Novo Holdings A/S | 2,569,379 | $67,549,000 | 3.35% |
| NEA Management Company, LLC | 2,444,379 | $64,263,000 | 2.72% |
| RA Capital Management | 2,003,653 | $52,676,000 | 0.96% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,150,299 | $30,241,000 | 0.74% |
| Rock Springs Capital Management LP | 879,954 | $23,134,000 | 0.59% |
| SPHERA FUNDS MANAGEMENT LTD. | 196,411 | $5,164,000 | 0.51% |
| Orbimed Advisors | 400,400 | $10,527,000 | 0.13% |